Compare Citius Pharmaceuticals Inc (CTXR) vs Southwest Airlines Co (LUV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Southwest Airlines Co — how do they compare? Citius Pharmaceuticals Inc trades at $0.53 (market cap $14.64M), while Southwest Airlines Co trades at $47.75 (market cap $23.25B). The key difference: Southwest Airlines Co is far larger — about 1588.1× Citius Pharmaceuticals Inc's market cap, and Southwest Airlines Co pays a 1.51% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | LUV | |
|---|---|---|
Market Cap | $14.64M | $23.25B |
Sector | Health | Industrials |
52-Week High | $1.82 | $54.80 |
52-Week Low | $0.53 | $29.06 |
Enterprise Value | $10.86M | $26.31B |
Dividend Yield | — | 1.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
Southwest Airlines (LUV) trades at $47.92, down 1.05% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $52.47 suggesting upside. Recent earnings show a mix of beats and a miss, with Q2 2026 results expected soon. The company maintains a solid balance sheet with a debt-to-asset ratio improving to 16.86% in 2025, though net cash flow remains negative due to significant financing activities.
The outlook is cautiously optimistic, driven by potential earnings growth and cost management, but risks include fuel price volatility and competitive pressures. Analyst sentiment is mixed, with 42% buy ratings, highlighting both recovery potential and near-term headwinds for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Southwest Airlines Co
Southwest Airlines is the largest domestic carrier in the United States, as measured by the number of originating passengers boarded. Southwest operates over 700 aircraft in an all-Boeing 737 fleet. Despite expanding into longer routes and business travel, the airline still specializes in short-haul leisure flights, using a point-to-point network. Southwest operates a low-cost carrier business model.
Read more on LUV →
